TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35168885

Group type: EXPERIMENTAL
Intervention: Violence prevention and education (VE)
Number of subjects: 2147

Group type: EXPERIMENTAL
Intervention: Violence prevention and education and health (VEH)
Number of subjects: 2147

Group type: EXPERIMENTAL
Intervention: Violence prevention, education, health, and wealth creation (VEHW)
Number of subjects: 2147

Group type: EXPERIMENTAL
Intervention: Pooled study arm (VE, VEH, VEHW)
Number of subjects: 2147

Group type: COMPARATOR
Intervention: Violence prevention only (V-only)
Number of subjects: 2147
Study: 33797485

Group type: EXPERIMENTAL
Intervention: Prehospital plasma transfusion
Number of subjects: 125

Group type: COMPARATOR
Intervention: Standard care resuscitation (crystalloid ± packed red blood cells)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Lactate (as a mediator)
Number of subjects: 125
Study: 35405352

Group type: EXPERIMENTAL
Intervention: PRN ranibizumab or bevacizumab treatment
Number of subjects: 363
Study: 33258168

Group type: EXPERIMENTAL
Intervention: Toothbrush and miswak (TB+M)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Toothbrush (TB)
Number of subjects: 20
Study: 32800078

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 1078

Group type: COMPARATOR
Intervention: Nicotine Patch
Number of subjects: 1078

Group type: COMPARATOR
Intervention: Combination Nicotine Replacement Therapy (Nicotine Patch and Lozenge)
Number of subjects: 1078
Study: 36343346

Group type: EXPERIMENTAL
Intervention: S-ICD
Number of subjects: 503

Group type: COMPARATOR
Intervention: TV-ICD
Number of subjects: 503
Study: 33885257

Group type: EXPERIMENTAL
Intervention: Upside-down recovery at +45°
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standing recovery at -20°
Number of subjects: 25
Study: 32087146

Group type: EXPERIMENTAL
Intervention: Fetal electrocardiography
Number of subjects: 218

Group type: COMPARATOR
Intervention: Standard external monitoring
Number of subjects: 218
Study: 36099501

Group type: EXPERIMENTAL
Intervention: Estetrol (15 mg) and Drospirenone (3 mg)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Ethinylestradiol (30 or 20 mcg) with Levonorgestrel (150 mcg)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Ethinylestradiol (30 or 20 mcg) with Drospirenone (3 mg)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Ethinylestradiol-containing products (with either Levonorgestrel or Drospirenone)
Number of subjects: 86
Study: 33152314

Group type: EXPERIMENTAL
Intervention: Dietary counseling plus 800 mg/day of docosahexaenoic acid (Group 1)
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Routine counseling plus 800 mg/day docosahexaenoic acid (Group 2)
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Dietary counseling plus 200 mg/day docosahexaenoic acid (Group 3)
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Routine counseling plus 200 mg/day docosahexaenoic acid (Group 4, control group)
Number of subjects: 1002
Study: 33234219

Group type: EXPERIMENTAL
Intervention: Mild hypothermia (34° to 35°C)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Conventional therapy (rewarmed to normal body temperature 36° to 37°C)
Number of subjects: 55
Study: 33863270

Group type: EXPERIMENTAL
Intervention: Catheter-directed thrombolysis (CDT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anticoagulation alone
Number of subjects: 0
Study: 36066142

Group type: EXPERIMENTAL
Intervention: Subgingival minocycline hydrochloride (MH) delivery with non-surgical mechanical debridement (NSMD)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Non-surgical mechanical debridement (NSMD) alone
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Subgingival minocycline hydrochloride (MH) delivery with NSMD
Number of subjects: 48
Study: 34441888

Group type: EXPERIMENTAL
Intervention: Manual therapy treatment
Number of subjects: 75

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 75

Group type: COMPARATOR
Intervention: Classic physiotherapy (stretching exercises, TENS and massage)
Number of subjects: 75
Study: 33763470

Group type: COMPARATOR
Intervention: ABCA1-labeled exosomal miR-193b levels in CSF of MCI and DAT patients
Number of subjects: 333

Group type: COMPARATOR
Intervention: ABCA1-labeled exosomal miR-193b levels in serum of MCI and DAT patients
Number of subjects: 333

Group type: COMPARATOR
Intervention: ABCA1-labeled exosomal miR-193b levels in serum of SCD patients
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: ABCA1 levels of exosomes from HT-22 cells and neurons
Number of subjects: 333
Study: 32820851

Group type: EXPERIMENTAL
Intervention: Psilocybin (230 μg/kg p.o.)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 35234828

Group type: COMPARATOR
Intervention: Combined Individual and Group Schema Therapy (IGST)
Number of subjects: 495

Group type: COMPARATOR
Intervention: Predominantly Group Schema Therapy (PGST)
Number of subjects: 495
Study: 34937613

Group type: EXPERIMENTAL
Intervention: CTZ (LSTR antibiotic paste)
Number of subjects: 70

Group type: COMPARATOR
Intervention: ZOE (Zinc oxide eugenol pulpectomy)
Number of subjects: 70
Study: 36052109

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Exercise group (control)
Number of subjects: 30
Study: 32915500

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Nomogram predictions
Number of subjects: 356
Study: 35976802

Group type: EXPERIMENTAL
Intervention: Pulsed nonthermal shortwave (radiofrequency) electromagnetic field therapy (RecoveryRx) applied for up to 30 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pulsed nonthermal shortwave (radiofrequency) electromagnetic field therapy
Number of subjects: 12
Study: 34865333

Group type: EXPERIMENTAL
Intervention: Combined therapy of warm acupuncture at back-shu points of five zang organs and escitalopram oxalate tablets (30 min each time, 5 times a week for 6 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Escitalopram oxalate tablets (administered orally every day for 6 weeks)
Number of subjects: 80
Study: 34229509

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) supplemented with intensive principle-based correctional counseling (PBCC)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 132
Study: 32567734

Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid 250 mg and oral ranitidine 150 mg twice daily, plus topical fluocinolone‐based combination cream (FbTC) once daily.
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo tablets (calcium lactate and multivitamin) and topical fluocinolone‐based combination cream (FbTC) once daily.
Number of subjects: 130
Study: 34417848

Group type: EXPERIMENTAL
Intervention: Deep convolutional neural network (DCNN) models
Number of subjects: 1016

Group type: COMPARATOR
Intervention: Radiomics models
Number of subjects: 1016
Study: 32627564

Group type: EXPERIMENTAL
Intervention: Psychoeducation and memory strategy practice
Number of subjects: 56

Group type: COMPARATOR
Intervention: Psychoeducation (active control)
Number of subjects: 56
Study: 32696598

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) therapy (2 L/kg/min)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Low-flow nasal oxygen cannula (LFNC, standard care)
Number of subjects: 50
Study: 616973848

Group type: EXPERIMENTAL
Intervention: Enfamil liquid human milk fortifier (ELHMF)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Similac liquid human milk fortifier (SLHMF)
Number of subjects: 31
Study: 33162348

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg of intravenous morphine during anesthetic induction
Number of subjects: 57

Group type: COMPARATOR
Intervention: Conventional anesthesia without morphine
Number of subjects: 57
Study: 33661918

Group type: EXPERIMENTAL
Intervention: Drug-eluting stent
Number of subjects: 9013

Group type: COMPARATOR
Intervention: Bare-metal stent
Number of subjects: 9013
Study: 36428277

Group type: EXPERIMENTAL
Intervention: Moisturizer applied three times daily on one side of the face
Number of subjects: 21

Group type: COMPARATOR
Intervention: No moisturizer (control side)
Number of subjects: 21
Study: 33439263

Group type: EXPERIMENTAL
Intervention: Remote Digital Monitoring (RDM) for reducing hypoglycemic episodes
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Remote Digital Monitoring (RDM) for preventing ophthalmologic complications
Number of subjects: 1010
Study: 35912196

Group type: EXPERIMENTAL
Intervention: Definitive chemoradiotherapy (dCRT) followed by surveillance and salvage esophagectomy only when needed
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Neoadjuvant chemoradiotherapy (nCRT) followed by mandatory surgery
Number of subjects: 1200
Study: 34574441

Group type: EXPERIMENTAL
Intervention: True Acupuncture (TA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham Acupuncture (SA)
Number of subjects: 20
Study: 32321718

Group type: EXPERIMENTAL
Intervention: CPC634 (75 mg/m2)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional docetaxel (75 mg/m2)
Number of subjects: 24
Study: 34082039

Group type: EXPERIMENTAL
Intervention: Oxytocin (OT)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 32147881

Group type: EXPERIMENTAL
Intervention: Topical glycopyrronium tosylate (GT) 2.4%
Number of subjects: 43

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 43
Study: 34743243

Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride (SDF)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Silver-modified atraumatic restorative treatment (SMART) sealants
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study: 34743671

Group type: EXPERIMENTAL
Intervention: LEG group (leg extension exercise)
Number of subjects: 0

Group type: COMPARATOR
Intervention: SMTH group (squats in the smith machine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 35316329

Group type: EXPERIMENTAL
Intervention: ROC-Stand
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: ROC-Sit
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conventional therapy (control)
Number of subjects: 39
Study: 33161831

Group type: EXPERIMENTAL
Intervention: Guideline-recommended disease management interventions including education of general practitioners, reimbursement of natriuretic peptide analysis, audits in EHR, training of HF educators, and structured transition protocol after discharge.
Number of subjects: 100000
Study: 35178880

Group type: EXPERIMENTAL
Intervention: Patient Concerns Inventory (PCI-HN)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Control group (no PCI-HN)
Number of subjects: 288
Study: 34744265

Group type: EXPERIMENTAL
Intervention: Cyclocryotherapy (CCT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Transscleral diode laser cyclophotocoagulation (TS‐DCPC)
Number of subjects: 40
Study: 32449277

Group type: EXPERIMENTAL
Intervention: Active vibrating capsule (5 capsules/week for 8 weeks)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Active mode 1 (vibrating capsule)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Sham capsule (5 capsules/week for 8 weeks)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Active vs. sham (study 1)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Active mode 1 vs. sham (study 2)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Active mode 2 vs. sham (study 2)
Number of subjects: 250
Study: 35437945

Group type: EXPERIMENTAL
Intervention: Crizotinib treatment with a low radiomics score
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Nomogram combining smoking history and radiomics signature
Number of subjects: 75
Study: 34588809

Group type: EXPERIMENTAL
Intervention: High-frequency impulse therapy (HFIT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 36
Study: 35466430

Group type: EXPERIMENTAL
Intervention: Eptinezumab 100 mg
Number of subjects: 1072

Group type: EXPERIMENTAL
Intervention: Eptinezumab 300 mg
Number of subjects: 1072

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1072
Study: 33356445

Group type: EXPERIMENTAL
Intervention: Vibegron 75 mg
Number of subjects: 506

Group type: COMPARATOR
Intervention: Tolterodine 4 mg
Number of subjects: 506
Study: 33828241

Group type: EXPERIMENTAL
Intervention: Daily supplementation of iron (60 mg), folic acid (500 mcg), and cyanocobalamin (1000 mcg) for 90 days
Number of subjects: 760

Group type: COMPARATOR
Intervention: Control group received iron and folic acid with placebo for 90 days
Number of subjects: 760

Group type: EXPERIMENTAL
Intervention: Daily supplementation of iron, folic acid, and vitamin B12 for 90 days
Number of subjects: 760
Study: 33080714

Group type: EXPERIMENTAL
Intervention: Pathological myopia group
Number of subjects: 290

Group type: COMPARATOR
Intervention: Emmetropic group
Number of subjects: 290
Study: 36271314

Group type: EXPERIMENTAL
Intervention: Gepotidacin (1500 mg) plus placebo, twice daily for 5 days
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Nitrofurantoin (100 mg) plus placebo, twice daily for 5 days
Number of subjects: 5000
Study: 35924110

Group type: EXPERIMENTAL
Intervention: Logistic regression model
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: XGBoost algorithm model
Number of subjects: 60
Study: 32755057

Group type: EXPERIMENTAL
Intervention: Men's dietary knowledge
Number of subjects: 1396

Group type: EXPERIMENTAL
Intervention: Men's education levels and distance to markets
Number of subjects: 1396
Study: 32465627

Group type: EXPERIMENTAL
Intervention: Hybrid thrombolytic approach (hTL) using alteplase infused at 1mg/min followed by maintenance infusion at 1mg/hour, median total alteplase dose was 74mg (IQR 48, 90mg).
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hybrid thrombolytic approach (hTL) using alteplase.
Number of subjects: 10
Study: 32604202

Group type: EXPERIMENTAL
Intervention: Virtual clinical encounters via video conference technology
Number of subjects: 52

Group type: COMPARATOR
Intervention: Traditional in-office clinical encounters
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Virtual clinical encounters
Number of subjects: 52
Study: 35126881

Group type: EXPERIMENTAL
Intervention: Physical activity condition
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-physical active control condition
Number of subjects: 120
Study: 34371880

Group type: EXPERIMENTAL
Intervention: Daily oral vitamin A and D drops (1800 IU vitamin A and 600 IU vitamin D2) for 2 months
Number of subjects: 245

Group type: COMPARATOR
Intervention: Matching placebo for 2 months
Number of subjects: 245
Study: 36112723

Group type: EXPERIMENTAL
Intervention: Probiotics (one capsule per day for 3 months)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 34179971

Group type: EXPERIMENTAL
Intervention: Follitropin delta (individualised fixed-dose regimen based on AMH level and body weight)
Number of subjects: 1009

Group type: EXPERIMENTAL
Intervention: Follitropin delta (individualised fixed-dose regimen)
Number of subjects: 1009
Study: 32334541

Group type: EXPERIMENTAL
Intervention: Life Review Therapy for Holocaust Survivors (LRT-HS) consisting of 20-25 sessions
Number of subjects: 80

Group type: COMPARATOR
Intervention: Supportive control group
Number of subjects: 80
Study: 35694836

Group type: EXPERIMENTAL
Intervention: Robot-assisted radical cystectomy (RARC)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Open radical cystectomy (ORC)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Both RARC and ORC
Number of subjects: 118
Study: 33030730

Group type: EXPERIMENTAL
Intervention: Saline + rifampicin
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Saline + 10% povidone iodine
Number of subjects: 300

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 300
Study: 34953768

Group type: EXPERIMENTAL
Intervention: Precision diagnostic strategy (pre‐test risk assessment using PROMISE Minimal Risk Tool, deferred testing for low-risk, cCTA with selective FFRCT for stenosis ≥30% and <90%)
Number of subjects: 2103

Group type: COMPARATOR
Intervention: Usual care diagnostic strategy (initial noninvasive or invasive test selected by clinical care team, no cCTA as initial strategy)
Number of subjects: 2103

Group type: EXPERIMENTAL
Intervention: Precision diagnostic strategy
Number of subjects: 2103

Group type: COMPARATOR
Intervention: Usual care diagnostic strategy
Number of subjects: 2103
Study: 32032218

Group type: EXPERIMENTAL
Intervention: AOSpine thoracolumbar spine injury classification system
Number of subjects: 25
Study: 34870587

Group type: EXPERIMENTAL
Intervention: PAP therapy with ≥ 4 hours of use on ≥ 70% of nights
Number of subjects: 119

Group type: COMPARATOR
Intervention: PAP therapy with < 4 hours of use or < 70% of nights
Number of subjects: 119
Study: 35710571

Group type: EXPERIMENTAL
Intervention: Partial twirling
Number of subjects: 2

Group type: COMPARATOR
Intervention: Standard randomized benchmarking
Number of subjects: 2
Study: 33374791

Group type: EXPERIMENTAL
Intervention: Clobetasol oral gel 0.05%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Anti-inflammatory mouthwash (calcium hydroxide, hyaluronic acid, umbelliferone, oligomeric pro-anthocyanidins)
Number of subjects: 40
Study: 35419166

Group type: EXPERIMENTAL
Intervention: Moderate-intensity treadmill exercise three times/week for three months with MIND diet
Number of subjects: 68

Group type: COMPARATOR
Intervention: MIND diet only
Number of subjects: 68
Study: 34603442

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg intravenous before skin incision
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 34894273

Group type: EXPERIMENTAL
Intervention: Remote Patient Management (RPM)
Number of subjects: 1538

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 1538
Study: 32075228

Group type: EXPERIMENTAL
Intervention: Enzogenol® 50 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Enzogenol® 400 mg
Number of subjects: 25
Study: 36760029

Group type: EXPERIMENTAL
Intervention: Soft tissue expander used in a separate surgery before bone grafting surgery
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group received treatment including single surgery of bone grafting associated with periosteal releasing incision
Number of subjects: 16
Study: 34313093

Group type: EXPERIMENTAL
Intervention: Critically important antimicrobials administered sub-therapeutically for prophylaxis and growth enhancement purposes.
Number of subjects: 2402
Study: 33238999

Group type: EXPERIMENTAL
Intervention: ISTp-DP
Number of subjects: 777

Group type: COMPARATOR
Intervention: IPTp-SP
Number of subjects: 777
Study: 35147813

Group type: EXPERIMENTAL
Intervention: Neurofeedback
Number of subjects: 17

Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 17
Study: 33710263

Group type: EXPERIMENTAL
Intervention: Menopausal hormone therapy (HT) including conjugated equine estrogens (E) alone for women without a uterus (n=560) and E plus medroxyprogesterone acetate (P) for those with an intact uterus (n=610)
Number of subjects: 1170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1170
Study: 35577478

Group type: EXPERIMENTAL
Intervention: Continue DMARD therapy after first dose vaccination
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Withhold DMARD therapy after first dose vaccination
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Continue DMARD therapy after second dose vaccination
Number of subjects: 181

Group type: COMPARATOR
Intervention: Control group (no DMARD therapy)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: tsDMARD therapy
Number of subjects: 181
Study: 33974920

Group type: EXPERIMENTAL
Intervention: Pre-workout supplement (SUPP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 10
Study: 32910107

Group type: EXPERIMENTAL
Intervention: Simulation-based training
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no simulation-based training)
Number of subjects: 33
Study: 36477362

Group type: EXPERIMENTAL
Intervention: sequential belimumab + rituximab
Number of subjects: 86

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 86

Group type: COMPARATOR
Intervention: belimumab
Number of subjects: 86

Group type: COMPARATOR
Intervention: rituximab
Number of subjects: 86
Study: 34195880

Group type: EXPERIMENTAL
Intervention: Genetically predicted high fat mass
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetically predicted high fat-free mass
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetically predicted fat mass, fat-free mass, and fat percentage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetically predicted fat-free mass
Number of subjects: 0
Study: 35960482

Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5 mg
Number of subjects: 4313

Group type: EXPERIMENTAL
Intervention: Tanezumab 5 mg
Number of subjects: 4313

Group type: EXPERIMENTAL
Intervention: Oral NSAIDs
Number of subjects: 4313

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4313
Study: 33232811

Group type: EXPERIMENTAL
Intervention: ATP only (Arm A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ATP and shock (Arm B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shock only (Arm C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Arm A vs Arm B
Number of subjects: 0

Group type: COMPARATOR
Intervention: Arm A vs Arm C
Number of subjects: 0
Study: 32716115

Group type: EXPERIMENTAL
Intervention: Home-use LED mask device and HA ampoule (Group A)
Number of subjects: 48

Group type: COMPARATOR
Intervention: HA ampoule only (Group B)
Number of subjects: 48
Study: 33908610

Group type: EXPERIMENTAL
Intervention: CARBO/ETO + HDCT
Number of subjects: 35

Group type: COMPARATOR
Intervention: Other treatments
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Localized disease (M0) with no residual tumor
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Localized disease (M0) with residual tumor
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Supratentorial location
Number of subjects: 35
Study: 33599777

Group type: EXPERIMENTAL
Intervention: High smoking motivation condition (nicotine-deprived and/or smoking cue exposure)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Low smoking motivation condition (non-deprived and/or control cue exposure)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High smoking motivation condition
Number of subjects: 90

Group type: COMPARATOR
Intervention: Low smoking motivation condition
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 90
Study: 33150744

Group type: EXPERIMENTAL
Intervention: LOW social status condition
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Food insecurity
Number of subjects: 133